Page 60 - Demo
P. 60
Conclusions
⚫ IMpassion130 is the first and only Phase III study to show the clinically meaningful benefit of first-line immunotherapy in mTNBC
⚫ TECENTRIQ + nab-paclitaxel sets a new benchmark as the first therapy to cross the 2-year landmark OS benefit in first-line therapy for PD-L1+ mTNBC
– A median OS improvement from 18 to 25 months was observed in the PD-L1+ population (HR, 0.71)
– Significant PFS benefit in the ITT and PD-L1+ populations
– 59% of PD-L1+ mTNBC patients achieved CR/PR with TECENTRIQ + nab-paclitaxel
⚫ PD-L1 IC status (≥ 1%) predicts clinical benefit with TECENTRIQ + nab-paclitaxel
⚫ TECENTRIQ + nab-paclitaxel was well tolerated, with no cumulative toxicities and no new- or late-onset
safety signals
TECENTRIQ + nab-paclitaxel is approved by the FDA1 and recommended for the treatment of patients with PD-L1 IC ≥ 1% mTNBC in the NCCN2 and AGO3 guidelines
1.Tecentriq (atezolizumab) [package insert]. South San Francisco, CA: 2. NCCN Clinical Practice Guidelines. Breast Cancer. V1.2019. Genentech USA, Inc; 2019. 3. AGO Guidelines Breast Version 2019.1.
⚫
